Skip to main content

Recognizing the Patterns in Strategic M&A during Down Markets

Monday, February 26, 2024
Majestic Complex
With biotechnology stock indexes down nearly ten percent and little IPO appetite, companies’ access to fresh capital is particularly constrained, creating opportunities and challenges for those fortunate firms with enough capital to pursue M&A as valuations have declined. Past biotechnology business cycles offer lessons, adjusted by recent clinical success trends, to identify critical success factors for strategic M&A for both the acquirer and acquired parties. Learn from experienced deal makers about what types of M&A makes most sense in this market for keeping clinical pipelines active on behalf of patients when alternative capital sources are unavailable.
Arda Ural, Americas Life Sciences Sector Leader - EY (Ernst & Young)
Kip Bitok, Director - Healthcare Investment Banking - Chardan Capital Markets
Anna Kazanchyan, Founder and Chief Executive Officer - Saghmos Therapeutics
Chadé Severin, Partner, Mergers and Acquisitions - Skadden
Mayukh Sukhatme, President & Chief Investment Officer - Roivant Sciences

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.